View Post

6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return

In Clinical Trials by Barbara Jacoby

By: Peter Thorley, University of Warwick From: medicalxpress.com A new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning. The majority of clinical trials in cancer assess either new treatments or additional treatments to the current standard …

View Post

Phase III NALA Trial Results in Higher PFS With Neratinib Combo for HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jason M. Broderick From: targetedonc.com Combining Neratinib (Nerlynx) with capecitabine (Xeloda) showed a 24% reduction in the risk of disease progression or death compared with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer who had previously received 2 lines of HER2-targeted therapy, according to the results of the phase III NALA trial presented at the 2019 …

View Post

MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced additional details of the results from the Phase 3 SOPHIA study of margetuximab in patients with …

View Post

Study uncovers unknown pathway for breast cancer recurrence

In In The News by Barbara Jacoby

From: business-standard.com The researchers have tracked treatment-resistant cancer cells that grow and spread after the breast cancer treatment. For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs. Now a team of researchers has filled …

View Post

Breast cancer study by UCR medical student could help patients live longer

In In The News by Barbara Jacoby

By: Iqbal Pittalwala From: ucr.edu A student at the University of California, Riverside, presented research results at the annual meeting of the American Association for Cancer Research, or AACR, in Atlanta showing that surgery is associated with higher survival rates for patients with HER2-positive stage 4 breast cancer compared with those who did not undergo surgery. The protein HER2, or …

View Post

Breast cancer drug approved for Australia

In Clinical Trials by Barbara Jacoby

By: AAP From: 9news.com.au Kate Harper wants to be around to watch her two young twin sons grow up. That’s why, after grappling with the feeling of helplessness that came with being diagnosed with breast cancer, she made a commitment. “I said right from the start – and my husband’s in agreement as well – that we would attack everything …

View Post

Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients Granted FDA Approval

In In The News by Barbara Jacoby

By: Jennifer Barrett From: pharmacytimes.com Officials with the FDA have approved trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) subcutaneous injection for certain patients with HER2-positive early and metastatic breast cancer, according to a press release. Trastuzumab and hyaluronidase-oysk is indicated for patients with early disease in combination with chemotherapy, and metastatic disease in combination with paclitaxel, or alone in patients who …

View Post

Collaboration Promises Better, More Accurate Breast Cancer Diagnostics

In In The News by Barbara Jacoby

From: PR Newswire Data-sharing result s in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results. The Health Exchange Market, or T.H.E.M.™, together with LabCorp, Konica Minolta, Inc. University of Rochester, Penn State Hershey Medical Center and Lebanon VA Medical Center, has presented significant findings in breast cancer research at the 2018 San Antonio …

View Post

uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.

In In The News by Barbara Jacoby

From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …